R&D channel feed

Tri­ci­da eye­ing sale, cost-cut­ting op­tions af­ter fail­ing high-stakes CKD wa­ger

3 years ago

Af­ter pulling IPO plans, Arti­va part­ners with Af­fimed to speed up NK cell ther­a­py com­bo

3 years ago
Deals
Cell/Gene Tx

Ex­sci­en­tia wants to bring its AI/ML ap­proach in­to the world of bi­o­log­ics. It's start­ing with an­ti­bod­ies

3 years ago
AI

Com­pass' sin­gle-dose psilo­cy­bin shows strong ef­fi­ca­cy in PhII treat­ment-re­sis­tant de­pres­sion tri­al

3 years ago

A high fly­er out of Flag­ship im­plodes — for the last time

3 years ago

Sur­face On­col­o­gy lays off 20% as biotech halts CD39 work on one of its ‘crown jew­els’

3 years ago
People

In spin­ning out can­cer pipeline, Alk­er­mes cites In­fla­tion Re­duc­tion Ac­t's hy­po­thet­i­cal in­cen­tives for bi­o­log­ics R&D

3 years ago
Deals

Rigel churns out an­oth­er late-stage clin­i­cal fail­ure — this time in Covid-19

3 years ago
Coronavirus

Up­dat­ed: GSK nabs pri­or­i­ty re­view on RSV vac­cine, kicks off show­down with Pfiz­er — while 'set­ting the bar high' on R&D

3 years ago
Pharma

Bet­ting on CD47 as oth­ers ditch the tar­get, ALX bor­rows up to $100M to push sole clin­i­cal drug for­ward

3 years ago
Financing

Covid-19 con­tin­ues to be­fud­dle Big Phar­ma as Ab­b­Vie ax­es PhI of an oral drug

3 years ago
Coronavirus

Up­dat­ed: Eli Lil­ly blames Biden's IRA for can­cer drug dis­con­tin­u­a­tion as the new phar­ma play­book takes shape

3 years ago
FDA+

Covid-19 spurred a his­toric vac­cine R&D ef­fort. What does it mean for fu­ture pan­demics?

3 years ago
Coronavirus
In Focus

Pfiz­er de­clares 'first-ever' PhI­II win for RSV vac­cine in in­fants — and it's steer­ing straight to FDA

3 years ago

A sin­gle in­jec­tion of Uni­ty's an­ti-ag­ing hy­poth­e­sis bears fruit in PhII, as piv­otal plans shape up

3 years ago

#CPHI22: Cell and gene man­u­fac­tur­ing ex­pect­ed to see a bump as it moves out of the pan­dem­ic

3 years ago

Af­ter years of ef­fort, Ac­tini­um meets pri­ma­ry end­point in piv­otal AML tri­al

3 years ago

J&J press­es pause on a part­ner's PhI prostate can­cer study, cut­ting off po­ten­tial Er­lea­da com­bo

3 years ago
Deals

A Dal­las biotech halts TIL ther­a­py tri­als — shares crater near­ly 30%

3 years ago
Cell/Gene Tx

Ab­b­Vie dis­cards PhI­Ib au­toim­mune drug from 10-year-old dis­cov­ery pact, cit­ing chron­ic tox­i­col­o­gy study

3 years ago

Pen­ny stock forges ahead with an NDA for Duchenne treat­ment, seek­ing pri­or­i­ty re­view

3 years ago
FDA+

Tak­ing on Big Phar­ma ri­vals, biotech start­up un­veils first-in-hu­man da­ta on ROS1 drug

3 years ago

As 'low­er than pro­ject­ed' da­ta send it back to the draw­ing board, Sanofi takes $1.6B hit on IL-2

3 years ago
Pharma

FDA rais­es ef­fi­ca­cy con­cerns with Y-mAb­s' po­ten­tial ther­a­py for pe­di­atric neu­rob­las­toma ahead of ODAC meet­ing

3 years ago
FDA+
First page Previous page 112113114115116117118 Next page Last page
A service from the Financial Times